---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003489"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:00:48.452347+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Catalyst Pharmaceuticals prices public offering of 10M shares at $15.00, raising $150M gross

## Summary
- Offering of 10,000,000 shares at $15.00 each, gross proceeds $150M; net proceeds ~$140.1M.
- Underwriters have 30-day option to purchase up to an additional 1.5M shares.
- Net proceeds to fund potential acquisition of new product candidates and general corporate purposes.
- Offering expected to close on January 9, 2024; underwriters include BofA Securities and Citigroup.

## SEC filing metadata
- accession: 0001193125-24-003489
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312524003489/0001193125-24-003489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312524003489/d149661d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003489
- JSON: https://secwatch.observer/filing/0001193125-24-003489.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003489.txt

## Key facts
- Material Agreements
  CATALYST PHARMACEUTICALS, INC. entered into Underwriting Agreement with BofA Securities, Inc. and Citigroup Global Markets, Inc., as representatives of the underwriters named in Schedule A to the Underwriting Agreement valued at 10,000,000 shares of the Company’s common stock, par value $0.001 per share, at a public offering pr (effective 2024-01-04).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: BofA Securities, Inc. and Citigroup Global Markets, Inc., as representatives of the underwriters named in Schedule A to the Underwriting Agreement
  - Value: 10,000,000 shares of the Company’s common stock, par value $0.001 per share, at a public offering pr
  - Effective: 2024-01-04
  source text: On January 4, 2024, Catalyst Pharmaceuticals, Inc. (the “ Company ”) entered into an Underwriting Agreement (the “ Underwriting Agreement ”) with BofA Securities, Inc. and Citigroup Global Markets, Inc., as representatives of the underwriters named in Schedule A to the Underwriting Agreement (collectively, the “ Underwriters ”), relating to the public offering, issuance and sale (the “ Offering ”) by the Company of 10,000,000 shares of the Company’s common stock, par value $0.001 per share (the “ Shares ”), at a public offering price of $15.00 per share, less underwriting discounts
  evidence_url: https://www.sec.gov/Archives/edgar/data/1369568/000119312524003489/0001193125-24-003489-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.